Evolutions in the HER2-Amplified CRC Treatment Landscape
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Real-World Use of HER2-Directed Therapies in Colorectal Cancers
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
HER2-Amplified Colorectal Cancer: Clinical Trial Data
A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.
Treatment Algorithm for Metastatic Colorectal Cancer
Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.
Role of Circulating Tumor DNA Testing in Colorectal Cancer
In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.
Role of HER2 Expression in Colorectal Cancer
A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.
Colorectal Cancer: An Overview on Molecular Profiling
Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.
Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes
Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
Future Directions for mCRC Management
Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.
Sequencing Therapy for Relapsed mCRC
Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.
Management of Relapsed mCRC
Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.
Dosing Strategies for Regorafenib for Patients With mCRC
Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.
Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC
Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.
Role of Maintenance Therapy in Advanced CRC
Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.
Using ICI Therapy in MSI-High mCRC
Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.
Selecting Frontline Therapy for Newly Diagnosed mCRC
Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.
Role of Genomic Testing in mCRC
Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.
Overview of Colorectal Cancer
Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.
Treatments for BRAF-Mutated mCRC
Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.
Second-Line Treatment of mCRC: Rechallenging Therapy
The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.
Preferences for Second-Line Therapy for mCRC
Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.
Maintenance Therapy for Metastatic CRC
Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.
Optimizing mCRC Treatment: Decision-Making With Patients
An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.
Initial Strategies for Assessing and Treating mCRC
Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.
Future of NTRK Fusions
Challenges for TRK Fusion–Targeting Agents
Acquired Resistance in TRK Fusion-Positive Cancers
Approaching Treatment for TRK Fusion–Positive Cancers
TRK Inhibitor in GI Cancers: Adverse Effect Profile
Efficacy of TRK Inhibitors
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512